Immunodermatology News

The FDA’s broad indication for the use of beremagene geperpavec therapy for the treatment of dystrophic epidermolysis bullosa may have large financial implications for payers, according to a study.

An association with long-term complete remission was found in patients with pemphigus who used rituximab as first-line therapy, according to an extension study.

The use of biologics to treat psoriasis does not affect antibody production after a patient has had a COVID infection or vaccination, according to a study.

As much as 43% of patients with systemic sclerosis demonstrate evidence of myopathy, while those with proximal weakness and higher creatine kinase exhibit worse function and survival, according to data.

In addition to cutting edge content, the 22nd annual South Beach Symposium has added a “unique session” that focuses on how the medical and cosmetic dermatologist can work together to holistically treat patients.

Intralesional immunotherapy shows potential as a treatment for cutaneous malignancies, including nonmelanoma skin cancer, according to a speaker at this year’s ODAC Dermatology, Aesthetic & Surgical Conference.

In patients with pemphigus vulgaris and pemphigus foliaceus, adjuvant immunoadsorption did not lessen the time to clinical remission, according to a study.

Journey Medical Corporation’s efforts to launch a new rosacea drug have received a boost of up to $20 million as the company has entered into a credit facility with an affiliate of SWK Holdings Corporation.

Acitretin in combination with topical triamcinolone acetonide 0.1% may be a better treatment option than triamcinolone acetonide alone for patients with oral lichen planus, according to a study.

IMIDomics and Bristol Myers Squibb have expanded their partnership to include Sjögren's syndrome and atopic dermatitis in their research and development efforts for inflammatory diseases, the companies announced in a press release.